Hi! I am Andrii Buvailo, and this is my weekly newsletter ‘Where Tech Meets Bio’ where I talk about technologies, breakthroughs, and great companies moving the industry forward.
If you've received it, then you either subscribed or someone forwarded it to you. If the latter is the case, subscribe by pressing this button:
Starting this week, I am introducing premium plans to keep this project afloat. Paid subscribers will have access to in-depth content with actionable industry insights about trends and notable companies. Going premium is also a way to support this project.
Now, let’s get to this week’s topics…
Can in vitro techniques replace animal testing?
Regardless of what your answer might be, last year, the US Congress passed the FDA Modernization Act 2.0, giving drug companies a path to propose in-vitro tests in the clinical trial application, subject to approval by the FDA. Essentially, the Act now allows consideration of alternatives to animal testing in certain cases. It indicates general tendency toward gradual minimization of animal testing in drug research, alghough we are in early days.
Anyway, this marks a significant change from the Federal Food, Drug, and Cosmetics Act of 1938, which required animal testing for all new drug development protocols. Proponents of this initiative claim that this shift allows for more modern and potentially more effective ways of evaluating the safety of new drugs.
And the important reason is, of course, minimizing the involvement of animals and ceasing the suffering of our little brothers. I totally support this quite noble goal.
Just a remark, though. Over several years of running BiopharmaTrend as an independent consulting boutique, I had numerous discussions with a significant number of drug discovery and biotech experts, conducted many interviews with KOLs, etc. More often than not, I heard an opinion that in vitro strategies of today were not quite ready to substitute animal testing, at least not for all therapeutic areas, and that the area of translational research was ‘plagued with failures’ when it came to the practical implementation of such modern tools as human cell cultures, organ-on-a-chip systems, functional systems, and computational models (artificial intelligence-based) to predict clinical outcomes. This is not a formal study of mine, by any account, and not even my opinion (which is still evolving on this subject). But the fact that some really experienced folks think that way makes me wonder if this is the case.
I’ll leave it for a broader discussion that I started here on LinkedIn (see comments section). The opinions of various experts are really contradictory there.
Anyway, let’s focus on a set of technologies that are certainly bringing us closer to an animal-free drug testing future.
Organ-on-a-chip Systems
Nearly two decades ago, a groundbreaking discovery in the field of biomedical research emerged, known as organ-on-a-chip technology, which quickly captivated the interest of scientists across the globe. Led by bioengineer Donald E. Ingber at Harvard University, this innovative approach aimed to recreate the complex structure and functions of human organs within laboratory settings. By using specialized techniques, researchers successfully developed miniature models of organs, opening up new possibilities for studying human physiology in the lab.
The National Institutes of Health's Tissue Chip for Drug Screening program began in 2010 as a five-year partnership among NIH, the Defense Advanced Research Projects Agency (DARPA), and the U.S. Food and Drug Administration (FDA). Since 2012, the program has been led and managed by the National Center for Advancing Translational Sciences (NCATS). This collaborative initiative brought together experts from various fields, including biology, engineering, and materials science, to accelerate the development of organ-on-a-chip models for drug discovery and toxicity testing. Through these joint efforts, scientists achieved significant milestones in replicating organ-level functions and understanding how different organs interact on these tiny systems.
In 2012 researchers from Harvard University's Wyss Institute unveiled an innovative "human-on-a-chip" platform. By combining multiple organ-on-a-chip models, such as the lung, heart, liver, and blood-brain barrier, this groundbreaking system provided a comprehensive representation of human organ systems. By mimicking organ interactions, this platform offered a more accurate environment for drug testing and disease modeling, laying the foundation for future biomedical research.
Nowadays, the field continues to evolve. Researchers are now embarking on a transition from organ-on-a-chip to an even more ambitious concept known as patient-on-a-chip. This innovative leap aims to replicate the complexity of an individual patient's physiology within a single integrated system. By incorporating patient-specific cells, genetic information, and utilizing artificial intelligence (AI) algorithms, scientists hope to create personalized models capable of predicting an individual's response to specific treatments or therapies.
Let us delve into the evolution of organ-on-a-chip technology, exploring key contributors to this field, and the emergence of patient-on-a-chip models.
What is organ-on-a-chip technology?
Imagine a technology that can recreate the complex environment of our organs on a tiny chip. That's exactly what organ-on-a-chip (OOC) technology does. It's a cutting-edge approach that mimics the structure and function of human organs in a laboratory setting. By synthesizing organ-like units on a chip, OOC technology can simulate the behavior and physiology of tissues and organs, bringing us closer to understanding how our bodies work. This exciting innovation has the potential to revolutionize drug development and screening, offering a more accurate and reliable alternative to traditional methods. With organ chips, we can overcome the limitations of 2D cell cultures and animal trials, which often fall short in accurately predicting human responses. By providing a more realistic environment for cells to grow and interact, organ chips can significantly reduce the failure rate in late-stage human trials, making drug development faster, more cost-effective, and ultimately delivering more effective treatments. The success of organ chips is made possible by advancements in 3D bioprinting, fluidic chips, and 3D cell culture techniques, with the latter allowing cells to thrive under conditions that closely resemble the human body.
From organ-on-a-chip to patient-on-a-chip
The high cost of drug development and safety testing is partly due to the limitations of current preclinical models. These models often fail to accurately represent how drugs behave in the human body, leading to potential side effects and unexpected outcomes. To address this, scientists are seeking alternatives to traditional cell cultures and animal testing. One promising approach is the use of organoids, which are 3D models formed by self-assembling stem cells into mini-organs. While organoids offer a more realistic representation of human biology, they still have limitations. They lack the dynamic nature of real organs and fail to simulate the interactions between different organs in the body.
Unlike static organoid cultures, organ chips allow for the flow of fluids, mimicking the dynamic exchange of nutrients and signals that occurs in living tissues. By integrating multiple mature tissues on a chip and enabling communication through fluid perfusion, scientists hope to create a more comprehensive "body on a chip" model that closely resembles human physiology.
In a recent study published in Nature Biomedical Engineering, researchers made significant progress towards this goal. They developed a multi-organ chip system that integrated mature heart, liver, bone, and skin tissues, allowing them to interact and communicate as they would in the human body. The tissues were cultured within their unique microenvironments, separated by an endothelial layer, and connected to a recirculating bloodstream. This setup enabled the tissues to communicate and maintain their phenotypes, providing a more realistic model for studying drug metabolism and toxicity.

While the multi-organ chip system is a remarkable achievement, there are still challenges to overcome. The current system includes only a limited number of tissues, limiting its ability to capture the complexity of the whole human physiology. Future research will focus on developing internal circulation systems to provide fluid flow for the engineered multi-organs. However, this groundbreaking advance brings us closer to the ultimate goal of creating patient-specific models for drug testing and personalized medicine. The potential of these organ chips is immense and holds promise for improving drug development and patient care in the future.
What are the leading organ-on-a-chip companies?
Since its inception, numerous organ-on-a-chip companies have emerged in this field, pushing the boundaries of innovation and making significant contributions to advancing our understanding of human biology.
Below, we will review some of the leading companies in the organ-on-a-chip space, focus on how artificial intelligence (AI) is enabling progress in this field, and review in more detail one promising startup that is bringing creative solutions to augment organ-on-a-chip systems.
One notable organ-on-a-chip company is Emulate, based in the US, has developed an automated bio-emulation platform that creates a micro-engineered living environment for studying neuronal and vascular endothelial cells. By combining micro-engineering techniques with living human cells, Emulate's platform offers a new way to comprehend the effects of diseases, medicines, chemicals, and foods on human health.
Another prominent company in the organ-on-a-chip landscape is a Swiss company called InSphero. InSphero provides 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology for in vitro testing. Their technology allows for the early detection of pharmaceutical and toxic risks, reducing the need for animal testing in the pharmaceutical and biotechnology industries.
Elveflow, led by CEO Guilhem Velvé Casquillas, is situated in Paris and specializes in fluid control tools for microsystems. Their offerings provide research labs and clinical diagnostic centers with precise control over microfluidic systems, enabling them to conduct experiments with a high level of accuracy.
Netherlands-based MIMETAS focuses on creating organ-on-a-chip products for compound testing, screening, and basic research. Their technology allows clinicians to test compounds on miniaturized organ models using 3D cell culture with continuous perfusion, offering a high-throughput approach.
MesoBiotech provides integrative solutions for research, teaching, and large-scale applications. Their sophisticated stem cell technologies involve creating artificial basement membranes consisting of gelatin nanofibers and functional proteins. These culture patches can be merged with microfluidic devices to produce organ-on-a-chip and microphysiological systems, which are essential for disease modeling, toxicity testing, drug screening, and regenerative medicine research.
AxoSim, with CEO Lowry Curley leading the way in the US, has developed a neurological drug discovery platform. Their platform focuses on preclinical pharmaceutical development and therapeutic development, simulating the in vivo nervous system in an in vitro setting. This provides an alternative to costly and ineffective animal testing and 2D models.

TARA Biosystems has developed a biotech platform that utilizes predictive cardiac tissue models to transform cardiac medication discovery. By using stem cells to create heart cells, TARA Biosystems enables the measurement of changes in human cardiac function without the need for human testing, accelerating the development of medicines. In April 2022, TARA Biosystems was aquired by Valo Health, to be incorporated into the latter's end-to-end AI in drug discovery platform Opal.
Artificial Intelligence + Organs-on-a-chip
Artificial intelligence (AI) can play a significant role in organ-on-a-chip systems by analyzing large amounts of data generated by these systems and providing insights that would be difficult to obtain through manual methods. AI techniques such as machine learning, deep learning, and computer vision can be used to analyze images of cells and tissues on the chips, predict cellular behavior, and identify patterns and trends in the data.
One application of AI in organ-chip systems is in the development and optimization of the microfabrication techniques used to create the chips. AI algorithms can be used to design and optimize the microscale structures on the chips, such as the size and shape of the channels and the distribution of cells.
AI can also be used to monitor and control the conditions on the chips, such as temperature, pH, and nutrient levels. This can help to ensure that the cells on the chips are kept in an optimal environment for growth and function. AI methods are essential for processing complex multimodal data obtainable from organ-on-a-chip systems.
An Israeli-based biotech company Quris has taken patient-on-a-chip drug testing to the next level by incorporating artificial intelligence (AI). Quris uses AI algorithms trained on vast amounts of data from the patient-on-a-chip systems to predict the safety and effectiveness of drugs. This could potentially streamline the drug development process and lead to safer and more efficient treatments. However, the widespread adoption of this technology by drug companies remains to be seen.
Organ chips go beyond just growing human tissues. They actively mimic the environment of the human body, with air and blood flowing through tiny channels. Some chips can even expand and contract tissues to simulate movements like breathing or digestion. By connecting different organ chips and allowing fluid transfer between them, researchers can create a microphysiological system that closely resembles the complex interactions between organs in the human body.
While challenges have existed in obtaining living human cells for the chips and designing more compact systems, recent advances have made these hurdles easier to overcome. Quris' systems, for example, are smaller and can fit up to a hundred "patients" on a single chip. By generating substantial data and training their AI algorithms, Quris aims to make predictions about drug safety. This integration of AI into organ chip systems has the potential to revolutionize drug development and improve success rates.
Despite the incredible potential of organ chips, the transition away from traditional animal testing methods has been gradual. Pharmaceutical companies are cautious about adopting new technologies due to the significant costs and risks involved. However, as more data becomes available to directly compare animal testing with patient-on-a-chip testing, companies may become more confident in making the switch. While animal testing may still be necessary for certain research questions, patient-on-a-chip technology offers a promising alternative, providing valuable insights into human cells and tissues.
Startup highlight: Bi/ond
One notable startup in organ-on-a-chip space is Bi/ond, that focuses on the development of microchips for biological innovation. They aim to improve medical treatments by providing hardware solutions that enable biomedical research reflecting our natural diversity. They seek to address the current gap in the medical field where treatments often ignore individual genetic variations. The microchips they build recreate key aspects of human organs such as the beating of a heart, tissue interactions, and blood circulation, enabling a more personalized approach to medicine.
They have developed a versatile organ-on-chip platform that is used for cultivating complex 3D tissues, such as organoids, ex vivo tissue, spheroids, and microtissues, as well as tissue-tissue interface models. This platform is designed to provide cutting-edge cell environments for biologists that demand high-quality results.
Bi/ond is also working on a project named ARinBIO. The project is designed to add more complexity to organ-on-chip and in vitro models by collecting data from sensors and using Augmented Reality (AR) to provide intuitive tools for researchers. The ultimate aim of this project is to improve the development of personalized medicine with a tool that enables complexity with an intuitive user experience. The AR technology is expected to radically change drug testing and data management in the biotech field. The project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824920.
The company was founded in 2017 by three co-founders, CSO William Fausto Quiros Solano, CTO Nikolas Gaio, and CEO Cinzia Silvestri, and is a spin-off of Delft University of Technology. Their product allows biologists to place individual cells on a computer chip, which can nourish, stimulate, and monitor the cells as though they were in the body. The patented organ-on-chip technology allows treatments to be optimized for different applications, including heart, lung, brain, and cancer tissues. In 2020, they secured €250,000 of growth capital from early-stage investment fund UNIIQ to expand their team, invest in research and development, and intellectual property activities.
As of 2022, Bi/ond had raised over $4 million in funding, including investment from the industrial venture firm FORWARD.one. The company's technology has been deployed across Europe, including at Leiden University Medical Center and Erasmus University Medical Center. The technology has been used to make heart tissues using Bi/ond’s microchips and to guide therapy for breast cancer patients. Bi/ond's organ-on-chip platform combines 3-D microfluidic cell cultures with a microchip to simulate the biological activity, mechanics, and physiological response of an entire organ or organ system.
The company's products include inCHIPit™, MUSbit™, and comPLATE™, and they have applications in the fields of muscle tissue, organoids, and tumor tissue.








